AKESO has announced that more than 40 clinical research outcomes for its portfolio of self-developed innovative drugs were officially presented at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting. The presentations centered on the company's pioneering bispecific antibody products, including cadonilimab (PD-1/CTLA-4) and ivonescimab (PD-1/VEGF), as well as next-generation CD47 monoclonal antibody candidate leflunomide. The research spanned multiple cancer types, such as non-small cell lung cancer, small cell lung cancer, colorectal cancer, renal cell carcinoma, melanoma, intestinal cancer, head and neck cancer, gynecological cancers, and biliary tract cancer, comprehensively demonstrating the breakthrough nature and broad clinical value of the company's innovative therapies.

The results from the HARMONi-6/AK112–306 study were prominently presented by the principal investigator, Professor Lu Shun, Director of the Oncology Department at Shanghai Chest Hospital, during the 2026 ASCO Plenary Session. The findings were simultaneously published in the leading international medical journal, *The Lancet*. This marks the first time in 61 years that Phase III clinical results for a first-in-class novel drug from China have been selected for a Late-Breaking Abstract (LBA) and an ASCO Plenary Session report. This signifies that the study not only represents a major theoretical breakthrough but is also poised to directly reshape clinical guidelines and practice.

HARMONi-6/AK112–306 (NCT 05840016 / CTR20231272) is a randomized, controlled, multicenter Phase III clinical trial evaluating ivonescimab combined with chemotherapy versus tislelizumab combined with chemotherapy as a first-line treatment for advanced squamous non-small cell lung cancer (sq-NSCLC). The primary endpoint of the study is progression-free survival (PFS) as assessed by an Independent Review Committee (IRRC) based on RECIST v1.1 criteria, with a key secondary endpoint being overall survival (OS).